Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey
暂无分享,去创建一个
J. Salleron | I. Pin | J. Dubus | L. Béghin | J. Just | C. Marguet | J. Derelle | D. Siret | A. Deschildre | G. Pouessel | J. Brouard | R. A. Taam | M. Fayon | L. Weiss | J. Rittié
[1] M. Mckean,et al. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma , 2012, Archives of Disease in Childhood.
[2] I. Annesi-Maesano,et al. Two novel, severe asthma phenotypes identified during childhood using a clustering approach , 2012, European Respiratory Journal.
[3] P. Gergen,et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. , 2011, The New England journal of medicine.
[4] H. Milgrom,et al. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma , 2011, Current medical research and opinion.
[5] J. Castro‐Rodriguez,et al. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. , 2011, Chest.
[6] G. Wennergren,et al. Assessment of problematic severe asthma in children , 2010, European Respiratory Journal.
[7] M. Cazzola,et al. Italian real-life experience of omalizumab. , 2010, Respiratory medicine.
[8] K. Carlsen,et al. Asthma severity in childhood, untangling clinical phenotypes * , 2010, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[9] J. Hébert,et al. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma , 2010, Current medical research and opinion.
[10] D. Caillaud,et al. Alternaria sensitization and allergic rhinitis with or without asthma in the French Six Cities study , 2010, Allergy.
[11] G. Wennergren,et al. Problematic severe asthma in children, not one problem but many: a GA2LEN initiative , 2009, European Respiratory Journal.
[12] B. Lanier,et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. , 2009, The Journal of allergy and clinical immunology.
[13] L. Dupont,et al. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. , 2009, Respiratory medicine.
[14] C. Marguet,et al. Control of asthma in children: still unacceptable? A French cross-sectional study. , 2009, Respiratory medicine.
[15] S. Tannenbaum,et al. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. , 2009, British journal of clinical pharmacology.
[16] P. Mowinckel,et al. Severe asthma in childhood: assessed in 10 year olds in a birth cohort study * , 2008, Allergy.
[17] E. Burchard,et al. Association between IgE levels and asthma severity among African American, Mexican, and Puerto Rican patients with asthma. , 2007, The Journal of allergy and clinical immunology.
[18] S. Szefler,et al. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. , 2006, The Journal of allergy and clinical immunology.
[19] S. Erzurum,et al. Features of severe asthma in school-age children: Atopy and increased exhaled nitric oxide. , 2006, The Journal of allergy and clinical immunology.
[20] B. Niggemann,et al. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study , 2006, The Lancet.
[21] R. Strange,et al. Asthma severity and atopy: how clear is the relationship? , 2006, Archives of Disease in Childhood.
[22] L. Borish,et al. Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[23] J Bousquet,et al. Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.
[24] W. Berger,et al. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[25] G. Roberts,et al. Food allergy as a risk factor for life-threatening asthma in childhood: a case-controlled study. , 2003, The Journal of allergy and clinical immunology.
[26] H. Milgrom,et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). , 2001, Pediatrics.
[27] J Bousquet,et al. Is sensitization to Alternaria alternata a risk factor for severe asthma? A population-based study. , 1999, The Journal of allergy and clinical immunology.
[28] R. Pauwels,et al. GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .
[29] M. Sears,et al. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. , 1991, The New England journal of medicine.